Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

Blood

Volumn 114, Issue 27, 2009, Pages 5444-5453

  Pagel, John M ^a,b   Gooley, Theodore A ^a   Rajendran, Joseph ^c   Fisher, Darrell R ^d   Wilson, Wendy A ^a   Sandmaier, Brenda M ^a,b   Matthews, Dana C ^a,b   Deeg, H Joachim ^a,b   Gopal, Ajay K ^a,b   Martin, Paul J ^a,b   Storb, Rainer F ^a,b   Press, Oliver W ^a,b   Appelbaum, Frederick R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BC 8 ANTIBODY I 131; CD 45 ANTIBODY I 131; CD3 ANTIGEN; CD33 ANTIGEN; FLUDARABINE; UNCLASSIFIED DRUG; CD45 ANTIGEN; DRUG DERIVATIVE; RADIOACTIVE IODINE; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; GROUPS BY AGE; HUMAN; HYPOTENSION; ISOTOPE LABELING; LIVER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; THROAT TIGHTNESS; VOMITING; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RISK FACTOR; SURVIVAL; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTIBODIES; ANTIGENS, CD45; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 71749102132     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-213298     Document Type: Article

References (57)

1. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531-4536.
2. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763.
3. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89(8):3048-3054.
4. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood. 2001;97(11):3390-3400.
5. Sandmaier BM, Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In: Blume KG, Forman SJ, eds. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Malden, MA: Blackwell Publishing Ltd; 2004:1164-1176.
6. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021-2030.
7. Niederwieser D, Maris M, Shizuru JA, et al. Lowdose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620-1629.
8. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(2):211-217.
9. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008:14(11):1279- 1287.
10. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24(3):444-453.
11. Gyurkocza B, Storb R, Storer B, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with de novo and secondary acute myeloid leukemia [abstract]. Blood. 2008;112(11):Abstract 149.
12. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246-255.
13. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110(7):2744-2748.
14. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94(4):1237-1247.
15. Pagel J, Gooley T, Rajendran J, et al. Targeted radiotherapy using 131I-anti-CD45 antibody followed by allogeneic hematopoietic cell transplantation (HCT): the relationships among dosimetry, bone marrow uptake, and relapse. Eur J Nucl Med Mol Imaging. 2006;33(supp 2):S193.
16. Pagel JM, Appelbaum FR, Eary JF, et al. 131Ianti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184-2191.
17. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9(3):478-490.
18. Appelbaum F, Matthews D, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54(5):829-833.
19. Waldmann TA, Pastan IH, Gansow OA, Junghans RP. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med. 1992;116(2):148-160.
20. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329(7):459-465.
21. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329(17):1219-1224.
22. Schwartz MA, Lovett DR, Redner A, et al. Doseescalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993;11(2):294-303.
23. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346(8971):336-340.
24. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alphaexpressing adult T-cell leukemia with Yttrium-90- labeled anti-Tac. Blood. 1995;86(11):4063-4075.
25. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976-2980.
26. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med. 1990;31(8):1257-1268.
27. Cancer Therapy Evaluation Program (National Cancer Institute) common toxicity criteria, version 2.0. http://ctep.info.nih.gov. Accessed March 1, 2009.
28. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34(4):689-694.
29. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1990;3:213.
30. Fisher DR, Badger CC, Brietz H, et al. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antibody Immunoconj Radiopharm. 1991;4:655.
31. Siegel JA, Pawlyk DA, Lee RE, et al. Tumor, red marrow, and organ dosimetry for 131I-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res. 1990;50(3 suppl):1039s-1042s.
32. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6(10):1562-1568.
33. Storer BE. Small-sample confidence sets for the MTD in a phase I clinical trial. Biometrics. 1993;49(4):1117-1125.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
35. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statist Med. 1999;18:695-706.
36. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
37. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
38. Martin PJ, McDonald GB, Sanders JE, et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):320-327.
39. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89(11):4226-4235.
40. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood. 1991;78(4):1125-1131.
41. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76(9):1867-1871.
42. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77(8):1660-1665.
43. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res. 1992;52(5):1228-1234.
44. Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood. 1991;78(7):1864-1874.
45. Rosario E, Rajendran J, Ruffner KL, et al. Radiolabeled anti-CD45 with cyclophosphamide (CY) and total body irradiation (TBI) followed by allogeneic hematopoietic stem cell transplantation (HSCT) for patients with advanced acute myeloid leukemia (AML) or myelodysplastic syndrome [abstract]. Blood. 2001;98(11):857a.
46. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103(1):78-84.
47. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of 'early-onset' graft-versushost disease following non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;129(3):381-391.
48. Wong R, Giralt SA, Martin T, et al. Reducedintensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102(8):3052-3059.
49. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82(6):336-342.
50. Sorror ML, Storer BE, Sandmaier BM, et al. Fiveyear follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
51. Pagel JM. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy. 2008;10(1):13-20.
52. van der Jagt RH, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 1992;52(1):89-94.
53. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med. 1980;152(4):842-852.
54. Taetle R, Ostergaard H, Smedsrud M, Trowbridge I. Regulation of CD45 expression in human leukemia cells. Leukemia. 1991;5(4):309-314.
55. Glatting G, Muller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med. 2006;47(8):1335-1341.
56. Jurcic JG. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm. 2000;15(4):319-326.
57. Jurcic J. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia [abstract]. J Clin Oncol. 2000;19:8a.